- Supported exchanges /
- SHE /
- 300199.SHE
Hybio Pharmaceutical (300199 SHE) stock market data APIs
Hybio Pharmaceutical Co., Ltd. engages in the development, manufacture, and commercialization of therapeutic peptides API and peptide-based drugs in China and internationally. It offers liraglutide, semaglutide, and exenatide for diabetes; terlipressin, desmopressin, and linaclotide for digestive tract and metabolic system; ganirelix, cetrorelix, and atosiban for obstetrics and gynecology; customized peptides; working standards for the peptide APIs and related impurities; peptide CRO; and CDMO services, which include peptide API synthesis and purification process development, finish dosage form development, reference standard preparation and qualification, impurity and product quality study and analysis, GMP system meeting EU and FDA standard, international and Chinese regulatory, and dossier support. The company was founded in 1998 and is based in Wuhan, China.
Hybio Pharmaceutical Financial Data Overview
| 11.72 | |
| 12.56 | |
| - | |
| 12.61 | |
| 11.69 | |
| 8.83-16.89 | |
| 10 352 M | |
| 883 M | |
| 405 M | |
| -0.0277 | |
| 0.699 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Hybio Pharmaceutical Fundamental Data is available in our Financial Data APIs
- Net Revenue 405 M
- EBITDA -88 458 424
- Earnings Per Share -0.42
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Hybio Pharmaceutical Earnings via APIs
- Latest Release 2024-10-29
- EPS/Forecast NaN
Get Hybio Pharmaceutical End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
